Evolent Health
EOLS Small CapHealthcare · Drug Manufacturers - Specialty & Generic
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolent Health Stock at a Glance
Evolent Health (EOLS) is currently trading at $6.99 with a market capitalization of $460.3M. The 52-week range spans from $3.86 to $10.20; the current price is 31.5% below the yearly high. Year-over-year revenue growth stands at +6.7%.
💰 Dividend
Evolent Health currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
6 analysts rate Evolent Health (EOLS) on consensus: None. The average price target is $14.67, implying +109.82% from the current price. Analyst price targets range from $10.00 to $20.00.
Evolent Health: The Investment Case in Detail
Evolent Health (EOLS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 66.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
The Bear Case
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
What to Watch Next
- The analyst consensus price target implies 109.82% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 66.05% — indicates pricing power
- –Currently unprofitable
- –Negative free cash flow
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to market-like volatility, elevated short interest (9.07%).
Trading Data
Related Stocks in the Same Sector
Evolus (EOLS) 2026: 6,50 USD US Performance-Beauty Aesthetic-Medical Specialist with Jeuveau Botulinum-Toxin Plus Evolysse Dermal-Filler Pipeline
The Real Story
Evolus Inc. (NASDAQ: EOLS) is a Newport Beach, California-headquartered performance-beauty company in the cash-pay aesthetic-medical market. Lead products: Jeuveau (proprietary 900-kilodalton purified botulinum-toxin Type A for glabellar lines, marketed in US, Canada, Europe, Australia), Evolysse (dermal-filler pipeline, FDA-pending). Direct-competitor positioning versus Allergan Botox and Revance Daxxify.
What Smart Money Thinks
Evolus has institutional base. BlackRock at approximately 6,4 percent, Vanguard at approximately 5,2 percent. Strathspey Crown historical sponsor. Short-interest sits at approximately 19 percent of float as of May 2026.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Jeuveau has captured approximately 14 percent US-aesthetic-botulinum-toxin market-share since 2019 launch, compounding revenue 25-35 percent annually.
Evolysse hyaluronic-acid dermal-filler pipeline (FDA-decision-expected late-2026) opens 2+ billion USD US-dermal-filler-TAM opportunity.
Cash-pay aesthetic-medical market provides structural-insulation from insurance-reimbursement cycles.
📉 The 3 Real Bear Points
Larger competitors compress Jeuveau pricing-power.
Negative book-value plus pre-profit operating burn create dilution risk.
FDA-approval slip would delay revenue-trajectory and compress fair-value.
Valuation in Context
Evolus at 6,50 USD per share with approximately 65,9 million shares outstanding has a market capitalization of approximately 428 million USD. Forward-P/E 24,4x.
Re-rating on Evolysse approval supports 12-16 USD price range — 85-145 percent upside. Bear-case 3-4 USD. Bull-case 18-24 USD.
🗓️ Next 3 Catalyst Dates
-
2026 Q3:
Q2 2026 earnings. Jeuveau growth.
-
2026 Q4:
Evolysse FDA approval decision.
-
2027 Q1:
Fiscal-2026 full-year plus 2027 guidance.
💬 Daniel's Take
Evolus is a aesthetic-medical-specialist with Jeuveau botulinum-toxin growth, Evolysse pipeline-catalyst and cash-pay defensive market. Position-sizing: 0,3–0,8 percent.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Evolent Health?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news